**Core Concept**
Respiratory Syncytial Virus (RSV) is a common cause of lower respiratory tract infections, particularly in infants and young children. Treatment is primarily supportive, with antiviral therapy being an emerging area of research.

**Why the Correct Answer is Right**
RSV is a single-stranded RNA virus that primarily affects the respiratory epithelium. Current treatment options are limited to supportive care, such as hydration, oxygen therapy, and mechanical ventilation in severe cases. Antiviral therapies like ribavirin have been explored, but their effectiveness is still being studied.

**Why Each Wrong Option is Incorrect**
**Option A:** Ribavirin is considered a treatment for RSV, although its efficacy is still being researched.
**Option B:** Palivizumab is a monoclonal antibody used for RSV prophylaxis in high-risk infants, not treatment.
**Option C:** Corticosteroids are not a first-line treatment for RSV infection.

**Clinical Pearl / High-Yield Fact**
RSV infection can lead to significant morbidity and mortality, especially in high-risk populations like premature infants and those with underlying respiratory conditions.

**Correct Answer: B. Palivizumab is used for RSV prophylaxis, not treatment.**